Progesterone Attenuates SIRT1-Deficiency-Mediated Pre-Eclampsia

Area of Science:

• Obstetrics and Gynecology
• Molecular Biology
• Pathophysiology

Background:

• Pre-eclampsia is a serious pregnancy complication characterized by hypertension and proteinuria.
• Sirtuin1 (SIRT1), a histone deacetylase, regulates critical cellular processes but its role in pre-eclampsia is unclear.

Purpose of the Study:

• To investigate the role of Sirtuin1 (SIRT1) in the pathogenesis of pre-eclampsia.
• To explore potential therapeutic strategies targeting SIRT1.

Main Methods:

• Quantified SIRT1 expression in pre-eclampsia patient samples.
• Utilized SIRT1 knockdown (SIRT1+/-) mice to model pre-eclampsia symptoms.
• Administered SIRT1 agonist SRT2104 and drugs like progesterone and metformin.
• Assessed trophoblast invasion and apoptosis.

Main Results:

• Reduced SIRT1 expression was observed in pre-eclampsia patients.
• SIRT1 knockdown mice exhibited pre-eclampsia-like symptoms (hypertension, proteinuria, fetal growth restriction, kidney injury, placental abnormalities).
• SIRT1 agonist SRT2104 improved these symptoms.
• Progesterone was more effective than metformin in ameliorating symptoms in SIRT1+/- mice.
• Progesterone promoted trophoblast invasion and inhibited apoptosis.

Conclusions:

• SIRT1 plays a significant role in pre-eclampsia development.
• Progesterone alleviates pre-eclampsia-like symptoms, potentially through a SIRT1-mediated pathway.
• Targeting SIRT1 or using progesterone may offer therapeutic benefits for pre-eclampsia.